Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detects prostate cancer in patients with prior negative TRUS biopsies

S. Vourganti1, N. Yerram1, J. Nix1, D. Volkin1, A. Hoang1, B. Turkbey3, A. Rastinehad1, G.N. Gupta1, J. Kruecker4, W.M. Linehan1, P.L. Choyke3, B.J. Wood2, P.A. Pinto1,2

1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD, USA
2 Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD, USA
3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda MD, USA
4 Philips USA, Briarcliff Manor NY, USA

Background: Patients with negative TRUS biopsies but have elevated PSA and a high clinical suspicion for prostate cancer create a diagnostic dilemma. The ability of multiparametric MRI and ultrasound (MRI/US) fusion biopsy to detect distinct lesions within the prostate may make it an effective tool in this challenging group of patients.

Methods: A review was performed on all patients undergoing MRI/US fusion biopsy from March 2007 to November 2011. All patients with one or more previous negative biopsies prior to presentation at our institution were included. Patients underwent 3 Tesla MRI of the prostate with endorectal coil and had a standard 12 core TRUS biopsy + targeted MRI/US fusion biopsy of concerning lesions.

Results: One hundred ninety-five patients had previous negative biopsies. Median age was 62 years (37–80), median number of previous biopsies was 2 (1–9), and median PSA was 9.13 ng/mL (0.3–103). Of the 195 pts, 73 (37%) were found to have cancer using both modalities at our institution. MRI/US fusion biopsy detected cancer in 59 pts (81%).

High grade cancer (Gleason 8 and above) was found in 21 of the 195 pts (11%). All 21 patients (100%) were detected on MRI/US fusion biopsy while TRUS biopsy missed 12 of these high grade cancers (55%).

Conclusions: Multiparametric MRI in conjunction with MR/US fusion biopsy platform is a novel diagnostic tool for detecting prostate cancer and may be ideally suited for patients with negative TRUS biopsies in the face of a persistent clinical suspicion for cancer.